Melphalan Flufenamide
A peptide-linked prodrug of melphalan designed to improve delivery into cancer cells, used to treat relapsed or refractory multiple myeloma and other blood cancers. The flufenamide component acts as a carrier that is cleaved by enzymes inside tumor cells, releasing melphalan to cause targeted DNA damage.
Peso molecular
498,4000 g/mol
LogP
3,20
TPSA
84,70 Ų
Regla de cinco de Lipinski
Cumple
Mecanismo de acción
Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.
Estructura 2D
Cite this structure
Embed this structure
SMILES
CCOC(=O)[C@H](Cc1ccc(F)cc1)NC(=O)[C@@H](N)Cc1ccc(N(CCCl)CCCl)cc1
InChI
InChI=1S/C24H30Cl2FN3O3/c1-2-33-24(32)22(16-18-3-7-19(27)8-4-18)29-23(31)21(28)15-17-5-9-20(10-6-17)30(13-11-25)14-12-26/h3-10,21-22H,2,11-16,28H2,1H3,(H,29,31)/t21-,22-/m0/s1
Molecular Formula
C24H30Cl2FN3O3
HBD / HBA
2 / 6
Enlaces Rotables
14
Átomos Pesados
33
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Preguntas frecuentes
A peptide-linked prodrug of melphalan designed to improve delivery into cancer cells, used to treat relapsed or refractory multiple myeloma and other blood cancers. The flufenamide component acts as a carrier that is cleaved by enzymes inside tumor cells, releasing melphalan to cause targeted DNA damage.
Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.
Yes, Melphalan Flufenamide is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4303060. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 9935639. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="melphalan-flufenamide"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/melphalan-flufenamide/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/melphalan-flufenamide/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/melphalan-flufenamide/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="melphalan-flufenamide"></drugfyi-drug>